Juan Ramirez Castaneda, MD
Neurology · San Antonio, TXNPI 1275797680
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $336,052 of the $456,425 with a category attached, or 73.6%. 29 manufacturers reported payments, led by MDD US Operations, LLC at 32.9% of the total. Among neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 730 payments — averaging $625.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$150K
- Amneal Pharmaceuticals LLC$86K
- AbbVie$75K
- Acorda Therapeutics, Inc$49K
- Boston Scientific$32K
- Abbott$28K
- plus $36K from 23 others
Across 120 payments — averaging $5723.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$259K
- AbbVie$209K
- Boston Scientific$181K
- Abbott$30K
- F. Hoffmann-la Roche AG$7K
- Teva Pharmaceuticals USA, Inc.$425
What the payments were for
- Consulting fees$40,9299%
- Speaking & faculty fees$336,05274%
- Travel & lodging$64,32014%
- Food & beverage$14,1003%
- Education$1,0230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 204 | $150,364 |
| Amneal Pharmaceuticals LLC | 77 | $85,644 |
| AbbVie | 115 | $75,170 |
| Acorda Therapeutics, Inc | 42 | $49,023 |
| Boston Scientific | 85 | $31,592 |
| Abbott | 61 | $28,333 |
| Acadia Pharmaceuticals Inc | 60 | $24,556 |
| Tanabe Pharma America, Inc. | 9 | $6,751 |
| Medtronic | 32 | $3,690 |
| Neurocrine Biosciences, Inc. | 16 | $523 |
| Teva Pharmaceuticals USA, Inc. | 5 | $170 |
| Lundbeck LLC | 1 | $65 |
| Kyowa Kirin, Inc. | 3 | $64 |
| Merz Pharmaceuticals, LLC | 2 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $56 |
| Ipsen Biopharmaceuticals, Inc | 2 | $49 |
| GE HealthCare | 2 | $43 |
| CSL Behring | 1 | $33 |
| Jazz Pharmaceuticals Inc. | 1 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $30 |
| Argenx US, Inc. | 1 | $28 |
| Merck | 1 | $27 |
| UCB, Inc. | 1 | $21 |
| Clearpoint Neuro, Inc. | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Insightec,inc | 1 | $16 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYTARY$62,601
- Duopa$53,217
- INBRIJA$48,473
- APOKYN$47,264
- NUPLAZID$23,564
- VYALEV$19,966
- VERCISE$14,971
- Neuromodulation Dspsbls and Accs$13,258
- INFINITY$10,045
- MYOBLOC$9,388
- CREXONT$5,592
- GENERAL DBS$3,871
- Xadago$3,117
- Infinity DBS Pulse Generators$2,324
- PROCLAIM$1,350
- PERCEPT PC BRAINSENSE$1,227
- GENERAL - THERAPIES$1,094
- Percept$939
- ACTIVA PC$741
- Proclaim Family of SCS IPGs$665
How this compares
$456,425 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 82 | $427,353 |
| RytaryCarbidopa/Levodopa | 168 | $298,321 |
| Droxidopa | 14 | $107,267 |
| InbrijaLevodopa | 15 | $77,716 |
| GocovriAmantadine Hcl | 12 | $52,352 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 465 | $12,553 |
| Rasagiline Mesylate | 89 | $9,592 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 169 | $4,923 |
| AmantadineAmantadine Hcl | 78 | $2,498 |
| RivastigmineRivastigmine Tartrate | 54 | $2,307 |
| Tetrabenazine | 14 | $2,185 |
| Clonazepam | 87 | $2,171 |
| Propranolol Hcl ErPropranolol Hcl | 73 | $1,947 |
| Propranolol Hcl | 90 | $1,360 |
| Primidone | 62 | $1,295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $24,556 | $427,35382 claims |
| Amneal Pharmaceuticals LLCRytary | $85,644 | $298,321168 claims |
| Acorda Therapeutics, IncInbrija | $49,023 | $77,71615 claims |
| MDD US Operations, LLCGocovri | $150,364 | $52,35212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 neurology providers in Texas.
Other neurology in San Antonio
- Ann BassSan Antonio$1.7M
- Santiago RestrepoSan Antonio$532K
- Eleni VaouSan Antonio$236K
- Eric PappertSan Antonio$166K
- Arash SalardiniSan Antonio$125K
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
- Pankaj SatijaHouston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.